AO

Artivion IncNYSE AORT Stock Report

Last reporting period 30 Sep, 2024

Updated 18 Nov, 2024

Last price

Market cap $B

1.068

Small

Exchange

XNYS - New York Stock Exchange, Inc

AORT Stock Analysis

AO

Uncovered

Artivion Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

28/100

Low score

Market cap $B

1.068

Dividend yield

1.13 %

Shares outstanding

40.556 B

Artivion, Inc. focuses on developing solutions that address cardiac and vascular surgeons' clinical challenges in treating patients with aortic diseases. The company is headquartered in Kennesaw, Georgia and currently employs 1,300 full-time employees. The firm's segments include Medical Devices and Preservation Services. The Medical Devices segment includes sales of aortic stent grafts, surgical sealants, and On-X. The Preservation Services segment includes services for the preservation of cardiac and vascular implantable human tissues. The company has four product families: aortic stent grafts, surgical sealants, On-X mechanical heart valves and related surgical products, and implantable cardiac and vascular human tissues. Aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Surgical sealants include BioGlue Surgical Adhesive (BioGlue) products. The company also sells or distributes PhotoFix bovine surgical patches.

View Section: Eyestock Rating